The market for buprenorphine and naloxone, commonly known by brand names like Suboxone, is driven by the ongoing opioid crisis and increasing efforts to treat opioid use disorder (OUD) [1][2]. This combination medication is a Schedule III controlled substance in the United States [3].
What is Buprenorphine and Naloxone Used For?
Buprenorphine and naloxone is primarily prescribed as a medication-assisted treatment (MAT) for opioid use disorder [1][4]. Buprenorphine, an opioid partial agonist, reduces cravings and withdrawal symptoms. Naloxone, an opioid antagonist, is included to deter misuse; if injected, it can precipitate withdrawal symptoms in individuals dependent on full opioid agonists [1][4]. It is also used for pain management, although this is a less common indication for the combination product compared to buprenorphine alone [5].
When Does Buprenorphine and Naloxone Patent Exclusivity End?
The patent landscape for buprenorphine and naloxone products is complex, with multiple patents covering the drug itself, its formulations, and manufacturing processes [6]. For instance, the original formulation of buprenorphine/naloxone film underwent patent expirations, leading to the availability of generic versions [7]. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals, which are critical for understanding market entry timelines for generic and biosimilar competitors [6].
Who Makes Buprenorphine and Naloxone?
Initially, buprenorphine and naloxone was developed and marketed by Reckitt Benckiser Pharmaceuticals (now Indivior) under the brand name Suboxone [8]. Following patent expirations and the introduction of generic versions, several pharmaceutical companies now manufacture and market buprenorphine and naloxone products, including generic films and tablets [7][9].
What is the Difference Between Buprenorphine and Naloxone and Other OUD Treatments?
Buprenorphine and naloxone is a form of Medication for Addiction Treatment (MAT) and is distinct from other OUD treatments. Unlike methadone, which is a full opioid agonist and typically administered at specialized clinics, buprenorphine/naloxone is a partial agonist that can be prescribed in office-based settings by qualified healthcare providers [10]. This accessibility can reduce barriers to treatment [10]. Other OUD treatments may include behavioral therapies without medication, or naltrexone, an opioid antagonist that blocks the effects of opioids [4].
What Are the Risks Associated with Buprenorphine and Naloxone?
Like other opioid medications, buprenorphine and naloxone carries risks, including the potential for misuse, dependence, and overdose, although the risk of overdose is lower than with full opioid agonists [1][3]. Side effects can include nausea, vomiting, constipation, headache, and withdrawal symptoms if not taken as prescribed [1]. Respiratory depression is a serious risk, especially when combined with other central nervous system depressants [3].
Can Buprenorphine and Naloxone Prescriptions Be Filled by Mail Order Pharmacies?
Yes, buprenorphine and naloxone prescriptions can generally be filled by mail-order pharmacies, provided the pharmacy is licensed and follows all regulations for dispensing controlled substances. This option can increase access to treatment for patients in remote areas or those with mobility challenges [11].